Healthcare providers must think about the entire home environment their patient lives in when prescribing opioids, said Jeffrey Gudin, MD, director of Pain Management and Palliative Care at Englewood Hospital and Medical Center.
Healthcare providers must think about the entire home environment their patient lives in when prescribing opioids, said Jeffrey Gudin, MD, director of Pain Management and Palliative Care at Englewood Hospital and Medical Center.
Transcript
How can healthcare providers balance the needs of patients with chronic pain while being mindful of the risks of opioid use disorder?
Well, balancing the needs of patients while being mindful for opioid use disorder is just that, balance. You can’t go out there with blinders on. You have to think that every patient is at risk and if your patient is not at risk, perhaps there someone in their household or immediate environment that’s at risk and the bottle of medications that you prescribe may be desirable to others. So we’re now thinking not just about the patient sitting in front of us but about the medical home, about the environment to which we’re going to prescribe in and I think that’s why being more cautious about how we prescribe opioids, who we prescribe them to, and selecting the right kind of medicine, like we have available abuse deterrent opioid formulations. We may be able to help shift the balance towards patients and away from abuse.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More